UTHR United Therapeutics Corporation

114.62
+0.72  (+1%)
Previous Close 113.9
Open 114.18
Price To Book 1.84
Market Cap 4995962342
Shares 43,587,178
Volume 466,751
Short Ratio
Av. Daily Volume 392,022

SEC filingsSee all SEC filings

  1. 8-K - Current report 181185941
  2. 8-K - Current report 181151842
  3. 8-K - Current report 181148599
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181148584
  5. 8-K - Current report 181123475

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 ongoing.
Tyvaso - INCREASE
Pulmonary hypertension associated with idiopathic pulmonary fibrosis (WHO Group 3)
Phase 3 unblinding of data March 2019
Esuberaprost - BEAT
Pulmonary arterial hypertension (PAH)
Phase 2/3 planned.
Aurora-GT - (eNOS gene therapy)
Pulmonary arterial hypertension (PAH)
Phase 3 data released August 8, 2018. Primary endpoint met.
Orenitram
Pulmonary arterial hypertension (PAH)
Refusal to file Letter (RTF) issued August 31, 2017. NDA to be resubmitted 1H 2019.
Trevyent
Pulmonary Arterial Hypertension (PAH)
Approved Dec 20 2013
Oral treprostinil
Pulmonary arterial hypertension (PAH)
Phase 3 ongoing. Licensed to UTHR November 15, 2018.
Ralinepag
Pulmonary Arterial Hypertension
Phase 3 portion of trial continues to enroll - noted February 21, 2018.
Unituxin - DISTINCT
Small cell lung cancer

Latest News

  1. See what the IHS Markit Score report has to say about United Therapeutics Corp.
  2. MoCo economic development officials plan satellite office in Boston
  3. Did United Therapeutics Corporation (NASDAQ:UTHR) Insiders Sell Shares?
  4. United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference
  5. Stocks down in December for pharma firms in the Triangle
  6. United Therapeutics Corporation (UTHR): Are Hedge Funds Right About This Stock?
  7. MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target
  8. Should You Be Excited About United Therapeutics Corporation’s (NASDAQ:UTHR) 20% Return On Equity?
  9. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - UTHR
  10. United Therapeutics (UTHR) Up 2% Since Last Earnings Report: Can It Continue?
  11. Health Canada Approves Unituxin® For The Treatment Of Pediatric High-Risk Neuroblastoma
  12. Analysts: Why United Therapeutics has had a streak of licensing deals
  13. United Therapeutics’ Product Portfolio in November
  14. CORV: Topline Growth Accelerating
  15. United Therapeutics: Recent Developments and Analysts’ Ratings
  16. Report: Exploring Fundamental Drivers Behind Harvard Bioscience, TTM Technologies, BSQUARE, United Therapeutics, KCAP Financial, and Gladstone Capital — New Horizons, Emerging Trends, and Upcoming Developments
  17. Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal
  18. My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy
  19. Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%
  20. Why Arena Pharmaceuticals Stock Is Soaring Today

SEC Filings

  1. 8-K - Current report 181185941
  2. 8-K - Current report 181151842
  3. 8-K - Current report 181148599
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181148584
  5. 8-K - Current report 181123475
  6. 8-K - Current report 181072311
  7. 8-K - Current report 181051156
  8. 8-K - Current report 181045634
  9. 8-K - Current report 181002904
  10. 8-K - Current report 18999661